{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:01:52Z","timestamp":1792728112733,"version":"4.5.0"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T00:00:00Z","timestamp":1536105600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["FS\/12\/53\/29643"],"award-info":[{"award-number":["FS\/12\/53\/29643"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.pharmthera.2018.08.004","type":"journal-article","created":{"date-parts":[[2018,8,4]],"date-time":"2018-08-04T02:52:10Z","timestamp":1533351130000},"page":"83-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Anti-platelet drugs and their necessary interaction with endothelial mediators and platelet cyclic nucleotides for therapeutic efficacy"],"prefix":"10.1016","volume":"193","author":[{"given":"Rebecca B.","family":"Knowles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy D.","family":"Warner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2018.08.004_bb0005","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1111\/jth.13738","article-title":"cGMP signaling inhibits platelet shape change through regulation of the RhoA-Rho Kinase-MLC phosphatase signaling pathway","volume":"15","author":"Aburima","year":"2017","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1055\/s-0038-1661134","article-title":"Platelet accumulation on collagen: Drugs which inhibit arachidonic acid metabolism and affect intracellular cyclic AMP levels","volume":"52","author":"Adams","year":"1984","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0015","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1111\/j.1538-7836.2005.01328.x","article-title":"Spatial and temporal dynamics of the endothelium","volume":"3","author":"Aird","year":"2005","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0020","doi-asserted-by":"crossref","first-page":"a006429","DOI":"10.1101\/cshperspect.a006429","article-title":"Endothelial cell heterogeneity","volume":"2","author":"Aird","year":"2012","journal-title":"Cold Spring Harbor Perspectives in Medicine"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0025","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1182\/blood-2014-09-599910","article-title":"Parmodulins inhibit thrombus formation without inducing endothelial injury caused by vorapaxar","volume":"125","author":"Aisiku","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0030","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0035","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJMoa041365","article-title":"Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction","volume":"351","author":"Anavekar","year":"2004","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0040","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1161\/CIRCRESAHA.107.165936","article-title":"Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: Potential implications for cyclooxygenase-2 inhibition","volume":"102","author":"Arehart","year":"2008","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0045","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1538-7836.2010.04160.x","article-title":"In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation","volume":"9","author":"Armstrong","year":"2011","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0050","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ahj.2016.09.006","article-title":"Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study","volume":"182","author":"Baber","year":"2016","journal-title":"American Heart Journal"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0055","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s12265-012-9435-y","article-title":"Novel antiplatelet agents: ALX-0081, a Nanobody directed towards von Willebrand factor","volume":"6","author":"Bartunek","year":"2013","journal-title":"Journal of Cardiovascular Translational Research"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0060","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1182\/blood-2013-07-512384","article-title":"Time-resolved characterization of cAMP\/PKA-dependent signaling reveals that platelet inhibition is a concerted process involving multiple signaling pathways","volume":"123","author":"Beck","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0065","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12964-016-0144-z","article-title":"Vasodilator-Stimulated Phosphoprotein (VASP)-dependent and -independent pathways regulate thrombin-induced activation of Rap1b in platelets","volume":"14","author":"Benz","year":"2016","journal-title":"Cell Communication and Signaling: CCS"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0070","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","article-title":"Intravenous platelet blockade with cangrelor during PCI","volume":"361","author":"Bhatt","year":"2009","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0075","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.2337\/db15-1141","article-title":"Glucagon-like peptide 1 receptor activation attenuates platelet aggregation and thrombosis","volume":"65","author":"Cameron-Vendrig","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0080","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1538-7836.2007.02356.x","article-title":"Inhibition of the platelet P2Y12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin","volume":"5","author":"Cattaneo","year":"2007","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0085","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/bcp.12826","article-title":"P2Y receptor blockade synergises strongly with nitric oxide and prostacyclin to inhibit platelet activation","volume":"81","author":"Chan","year":"2016","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0090","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1126\/science.1068711","article-title":"Role of prostacyclin in the cardiovascular response to thromboxane A2","volume":"296","author":"Cheng","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0095","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0100","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1056\/NEJM199105303242203","article-title":"Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease","volume":"324","author":"Dinh-Xuan","year":"1991","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0105","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.tips.2012.07.004","article-title":"Platelet GPVI: A target for antithrombotic therapy?!","volume":"33","author":"Dutting","year":"2012","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0110","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/nature12722","article-title":"Dysfunctional nitric oxide signalling increases risk of myocardial infarction","volume":"504","author":"Erdmann","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0115","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1172\/JCI110814","article-title":"Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man","volume":"71","author":"FitzGerald","year":"1983","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0120","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.tips.2017.05.001","article-title":"Targeting PAR1: Now what?","volume":"38","author":"Flaumenhaft","year":"2017","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0125","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/ATVBAHA.114.303410","article-title":"Therapeutic implications of protein disulfide isomerase inhibition in thrombotic disease","volume":"35","author":"Flaumenhaft","year":"2015","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0130","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJM197605132942001","article-title":"Lung function and risk of myocardial infarction and sudden cardiac death","volume":"294","author":"Friedman","year":"1976","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0135","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1172\/JCI81470","article-title":"A chimeric platelet-targeted urokinase prodrug selectively blocks new thrombus formation","volume":"126","author":"Fuentes","year":"2016","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0140","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/288373a0","article-title":"The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine","volume":"288","author":"Furchgott","year":"1980","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0145","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1161\/CIRCRESAHA.114.301808","article-title":"Thiol isomerases in thrombus formation","volume":"114","author":"Furie","year":"2014","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0150","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1182\/blood-2003-09-3349","article-title":"Potent inhibition of human platelets by cGMP analogs independent of cGMP-dependent protein kinase","volume":"103","author":"Gambaryan","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0155","doi-asserted-by":"crossref","first-page":"D82","DOI":"10.1016\/j.jacc.2013.10.026","article-title":"New trial designs and potential therapies for pulmonary artery hypertension","volume":"62","author":"Gomberg-Maitland","year":"2013","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0160","doi-asserted-by":"crossref","first-page":"14606","DOI":"10.1016\/S0021-9258(18)33319-2","article-title":"Evidence that changes in platelet cyclic AMP levels regulate the fibrinogen receptor on human platelets","volume":"257","author":"Graber","year":"1982","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0165","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","article-title":"Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: The ONSET\/OFFSET study","volume":"120","author":"Gurbel","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0170","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1161\/01.CIR.0000072771.11429.83","article-title":"Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity","volume":"107","author":"Gurbel","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0175","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/S0140-6736(79)92388-2","article-title":"Production of 6-oxo-PGF1 alpha by human lung in vivo","volume":"2","author":"Hensby","year":"1979","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0180","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1182\/blood-2012-08-449694","article-title":"Delayed targeting of CD39 to activated platelet GPIIb\/IIIa via a single-chain antibody: Breaking the link between antithrombotic potency and bleeding?","volume":"121","author":"Hohmann","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0185","first-page":"1082","article-title":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"70","author":"Ibanez","year":"2017","journal-title":"Revista Espanola Cardiology (England Ed)"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0190","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/0006-291X(83)91518-8","article-title":"Evidence that cyclic AMP may regulate Ca2+\u2212mobilization and phospholipases in thrombin-stimulated human platelets","volume":"112","author":"Imai","year":"1983","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0195","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1182\/blood-2004-03-1058","article-title":"Protein kinase A mediates inhibition of the thrombin-induced platelet shape change by nitric oxide","volume":"104","author":"Jensen","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0200","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/leu.2014.247","article-title":"Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation","volume":"29","author":"Kamel","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0205","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1136\/bmj.332.7553.1302","article-title":"Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials","volume":"332","author":"Kearney","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0210","doi-asserted-by":"crossref","first-page":"15782","DOI":"10.1073\/pnas.1218880110","article-title":"Blockade of the purinergic P2Y12 receptor greatly increases the platelet inhibitory actions of nitric oxide","volume":"110","author":"Kirkby","year":"2013","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0215","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.jacc.2010.10.035","volume":"57","author":"Lee","year":"2011","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0220","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S0021-9258(19)75924-9","article-title":"Agents that elevate cAMP levels in platelets decrease thrombin binding","volume":"262","author":"Lerea","year":"1987","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0225","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1161\/ATVBAHA.114.303724","article-title":"RUC-4: A novel alphaIIbbeta3 antagonist for prehospital therapy of myocardial infarction","volume":"34","author":"Li","year":"2014","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0230","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1055\/s-0037-1613448","article-title":"Differential regulation of P-selectin expression by protein kinase A and protein kinase G in thrombin-stimulated human platelets","volume":"89","author":"Libersan","year":"2003","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0235","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1161\/ATVBAHA.111.241067","article-title":"Platelet glycoprotein VI dimerization, an active process inducing receptor competence, is an indicator of platelet reactivity","volume":"32","author":"Loyau","year":"2012","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0240","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1161\/STROKEAHA.111.616649","article-title":"The von Willebrand inhibitor ARC1779 reduces cerebral embolization after carotid endarterectomy: A randomized trial","volume":"42","author":"Markus","year":"2011","journal-title":"Stroke"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0245","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrcardio.2017.206","article-title":"Current and future antiplatelet therapies: Emphasis on preserving haemostasis","volume":"15","author":"McFadyen","year":"2018","journal-title":"Nature Reviews. Cardiology"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0250","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","article-title":"Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial","volume":"374","author":"Mega","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0255","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nrd1929","article-title":"COX isoforms in the cardiovascular system: Understanding the activities of non-steroidal anti-inflammatory drugs","volume":"5","author":"Mitchell","year":"2006","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0260","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.amjcard.2009.07.014","article-title":"Impact of clinical and subclinical peripheral arterial disease in mid-term prognosis of patients with acute coronary syndrome","volume":"104","author":"Morillas","year":"2009","journal-title":"The American Journal of Cardiology"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0265","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","article-title":"Vorapaxar in the secondary prevention of atherothrombotic events","volume":"366","author":"Morrow","year":"2012","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0270","doi-asserted-by":"crossref","first-page":"F235","DOI":"10.1152\/ajprenal.00454.2004","article-title":"Prostacyclin signaling in the kidney: Implications for health and disease","volume":"289","author":"Nasrallah","year":"2005","journal-title":"American Journal of Physiology. Renal Physiology"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0275","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/j.1538-7836.2008.02976.x","article-title":"Ex vivo inhibition of thrombus formation by an anti-glycoprotein VI Fab fragment in non-human primates without modification of glycoprotein VI expression","volume":"6","author":"Ohlmann","year":"2008","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0280","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1093\/eurheartj\/ehr113","article-title":"Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: A randomized, double-blind, phase II trial","volume":"32","author":"Oldgren","year":"2011","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0285","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1160\/TH03-09-0588","article-title":"Endothelial nitric oxide synthase plays a minor role in inhibition of arterial thrombus formation","volume":"93","author":"Ozuyaman","year":"2005","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0290","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1160\/th14-01-0040","article-title":"Effect of adjunctive dipyridamole to DAPT on platelet function profiles in stented patients with high platelet reactivity. The result of the ACCEL-DIP Study","volume":"112","author":"Park","year":"2014","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0295","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1172\/JCI110576","article-title":"Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects","volume":"69","author":"Patrignani","year":"1982","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0300","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1056\/NEJMra052717","article-title":"Low-dose aspirin for the prevention of atherothrombosis","volume":"353","author":"Patrono","year":"2005","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0305","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1476-5381.1987.tb11367.x","article-title":"The anti-aggregating properties of vascular endothelium: Interactions between prostacyclin and nitric oxide","volume":"92","author":"Radomski","year":"1987","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0310","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/j.1538-7836.2005.01217.x","article-title":"Vitronectin stabilizes thrombi and vessel occlusion but plays a dual role in platelet aggregation","volume":"3","author":"Reheman","year":"2005","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0315","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.prostaglandins.2015.04.008","article-title":"Prostacyclin receptors: Transcriptional regulation and novel signalling mechanisms","volume":"121","author":"Reid","year":"2015","journal-title":"Prostaglandins & Other Lipid Mediators"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0320","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/j.1365-2125.1989.tb03544.x","article-title":"Differential effect of aspirin on thromboxane and prostaglandin biosynthesis in man","volume":"28","author":"Ritter","year":"1989","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0325","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/978-3-642-29423-5_9","article-title":"Targeting phosphodiesterases in anti-platelet therapy","author":"Rondina","year":"2012","journal-title":"Handbook of Experimental Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0330","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1160\/TH11-05-0319","article-title":"Differentiation of cGMP-dependent and -independent nitric oxide effects on platelet apoptosis and reactive oxygen species production using platelets lacking soluble guanylyl cyclase","volume":"106","author":"Rukoyatkina","year":"2011","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0335","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.amjcard.2006.09.112","article-title":"Impact of chronic obstructive pulmonary disease on post-myocardial infarction outcomes","volume":"99","author":"Salisbury","year":"2007","journal-title":"The American Journal of Cardiology"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0340","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1161\/CIRCULATIONAHA.112.000799","article-title":"Integrin alpha6beta1 is the main receptor for vascular laminins and plays a role in platelet adhesion, activation, and arterial thrombosis","volume":"128","author":"Schaff","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0345","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S0006-2952(01)00760-2","article-title":"Taming platelets with cyclic nucleotides","volume":"62","author":"Schwarz","year":"2001","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0350","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nature12613","article-title":"A directional switch of integrin signalling and a new anti-thrombotic strategy","volume":"503","author":"Shen","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0355","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1538-7836.2011.04576.x","article-title":"Novel roles of cAMP\/cGMP-dependent signaling in platelets","volume":"10","author":"Smolenski","year":"2012","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0360","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1182\/blood-2012-09-457739","article-title":"Hierarchical organization in the hemostatic response and its relationship to the platelet-signaling network","volume":"121","author":"Stalker","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0365","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1161\/CIRCULATIONAHA.110.981738","article-title":"Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease","volume":"123","author":"Stasch","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0370","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1161\/ATVBAHA.114.303408","article-title":"Targeting glycoprotein VI and the immunoreceptor tyrosine-based activation motif signaling pathway","volume":"34","author":"Stegner","year":"2014","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0375","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0140-6736(13)61170-8","article-title":"Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): A prospective multicentre registry study","volume":"382","author":"Stone","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0380","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2174\/138161206776361318","article-title":"Biology and pharmacology of the platelet P2Y12 receptor","volume":"12","author":"Storey","year":"2006","journal-title":"Current Pharmaceutical Design"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0385","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1016\/j.jacc.2013.07.101","article-title":"Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding","volume":"62","author":"Tantry","year":"2013","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0390","series-title":"Principles of anatomy & physiology","author":"Tortora","year":"2011"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0395","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1109719","article-title":"Thrombin-receptor antagonist vorapaxar in acute coronary syndromes","volume":"366","author":"Tricoci","year":"2012","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0400","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1160\/TH13-02-0084","article-title":"Novel antiplatelet drugs in clinical development","volume":"110","author":"Ungerer","year":"2013","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0405","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1161\/CIRCULATIONAHA.110.980623","article-title":"Novel antiplatelet drug revacept (Dimeric Glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans","volume":"123","author":"Ungerer","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0410","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/0140-6736(92)90865-Z","article-title":"Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure","volume":"339","author":"Vallance","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0415","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.4244\/EIJY15M11_07","article-title":"Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: Rationale and design of the GLOBAL LEADERS trial","volume":"12","author":"Vranckx","year":"2016","journal-title":"EuroIntervention"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0420","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0014-2999(89)90165-9","article-title":"Cyclic nucleotide elevating vasodilators inhibit platelet aggregation at an early step of the activation cascade","volume":"159","author":"Waldmann","year":"1989","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0425","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0430","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1365-2125.2011.03943.x","article-title":"Anti-platelet therapy: Cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy","volume":"72","author":"Warner","year":"2011","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0435","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0440","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.abb.2009.02.014","article-title":"Role of cAMP-dependent protein kinase in the regulation of platelet procoagulant activity","volume":"485","author":"Yan","year":"2009","journal-title":"Archives of Biochemistry and Biophysics"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0445","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0450","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2337\/diab.30.2.S24","article-title":"The endothelial cells of large and small blood vessels","volume":"30","author":"Zetter","year":"1981","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2018.08.004_bb0455","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood-2016-07-729400","article-title":"The integrin PSI domain has an endogenous thiol isomerase function and is a novel target for antiplatelet therapy","volume":"129","author":"Zhu","year":"2017","journal-title":"Blood"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725818301360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725818301360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T06:35:40Z","timestamp":1717223740000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725818301360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":91,"alternative-id":["S0163725818301360"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2018.08.004","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-platelet drugs and their necessary interaction with endothelial mediators and platelet cyclic nucleotides for therapeutic efficacy","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2018.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}